262 related articles for article (PubMed ID: 4130153)
1. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
Stitzel AE; Spitzer RE
J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
[No Abstract] [Full Text] [Related]
2. Blocking of the hemolytic expression of the classical complement sequence by products of complement activation via the alternate pathway. Materials responsible for the blocking phenomenon and their proposed mechanism of action.
Koethe SM; Austen KF; Gigli I
J Immunol; 1973 Feb; 110(2):390-400. PubMed ID: 4684033
[No Abstract] [Full Text] [Related]
3. Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. II. Evidence for involvement of C1 and components of the alternate complement pathway.
May JE; Frank MM
J Immunol; 1973 Dec; 111(6):1668-76. PubMed ID: 4750863
[No Abstract] [Full Text] [Related]
4. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
[No Abstract] [Full Text] [Related]
5. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
[No Abstract] [Full Text] [Related]
6. Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.
Götze O; Medicus RG; Müller-Eberhard HJ
J Immunol; 1977 Feb; 118(2):525-32. PubMed ID: 839069
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of Guinea pig properidin.
Nicholson A; Austen KF
J Immunol; 1977 Jan; 118(1):103-8. PubMed ID: 830742
[TBL] [Abstract][Full Text] [Related]
8. The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.
Brade V; Nicholson A; Lee GD; Mayer MM
J Immunol; 1974 May; 112(5):1845-54. PubMed ID: 4818461
[No Abstract] [Full Text] [Related]
9. Anaphylatoxin formation by contact activation of plasma. 3. Fixation of two different anaphylatoxin-forming complexes on zymosan.
Brade V; Schmidt G; Vogt W
Eur J Immunol; 1972 Apr; 2(2):180-6. PubMed ID: 4644242
[No Abstract] [Full Text] [Related]
10. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
11. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
Brade V; Nicholson A; Bitter-Suermann D; Hadding U
J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
[No Abstract] [Full Text] [Related]
12. Changes in the immunochemical properties of highly purified properdin in human serum.
Minta JO
J Immunol; 1975 Apr; 114(4):1415-21. PubMed ID: 123262
[TBL] [Abstract][Full Text] [Related]
13. DNP-antigens activate the alternate pathway of the complement system.
König W; Bitter-Suermann D; Dierich M; Limbert M; Schorlemmer HU; Hadding U
J Immunol; 1974 Aug; 113(2):501-6. PubMed ID: 4858625
[No Abstract] [Full Text] [Related]
14. Interaction of properdin convertase and properdin in the alternative pathway of complement activation.
Spitzer RE; Stitzel AE; Urmson J
Immunochemistry; 1976 Jan; 13(1):15-20. PubMed ID: 943370
[No Abstract] [Full Text] [Related]
15. Activation of the alternative (properdin) pathway by divalent cations.
Lew FT; Yukiyama Y; Waks HS; Osler AG
J Immunol; 1975 Sep; 115(3):884-8. PubMed ID: 807649
[TBL] [Abstract][Full Text] [Related]
16. Studies on the properdin system: isolation of a heat-labile factor from guinea pig serum related to a human glycine rich beta-glycoprotein (GBG or factor B).
Brade V; Cook CT; Shin HS; Mayer MM
J Immunol; 1972 Dec; 109(6):1174-81. PubMed ID: 4628703
[No Abstract] [Full Text] [Related]
17. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.
Des Prez RM; Bryan CS; Hawiger J; Colley DG
Infect Immun; 1975 Jun; 11(6):1235-43. PubMed ID: 806523
[TBL] [Abstract][Full Text] [Related]
18. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
Schreiber RD; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
[TBL] [Abstract][Full Text] [Related]
19. Alternate complement pathways.
Osler AG; Sandberg AL
Prog Allergy; 1973; 17(0):51-92. PubMed ID: 4277357
[No Abstract] [Full Text] [Related]
20. Inhibition by cinnarizine of the properdin-dependent activation of complement.
Di Perri T; Auteri A; Pasini FL; Mattioli F
Arch Int Pharmacodyn Ther; 1977 Apr; 226(2):281-5. PubMed ID: 879911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
